CA3069167C - Composition for wound healing - Google Patents

Composition for wound healing Download PDF

Info

Publication number
CA3069167C
CA3069167C CA3069167A CA3069167A CA3069167C CA 3069167 C CA3069167 C CA 3069167C CA 3069167 A CA3069167 A CA 3069167A CA 3069167 A CA3069167 A CA 3069167A CA 3069167 C CA3069167 C CA 3069167C
Authority
CA
Canada
Prior art keywords
wound healing
composition
hydrolyzed collagen
topical composition
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3069167A
Other languages
French (fr)
Other versions
CA3069167A1 (en
Inventor
George D. Petito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA3069167A priority Critical patent/CA3069167C/en
Publication of CA3069167A1 publication Critical patent/CA3069167A1/en
Application granted granted Critical
Publication of CA3069167C publication Critical patent/CA3069167C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/01Hydrolysed proteins; Derivatives thereof
    • A61K38/012Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20Milk; Whey; Colostrum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/60Fish, e.g. seahorses; Fish eggs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/63Arthropods
    • A61K35/64Insects, e.g. bees, wasps or fleas
    • A61K35/644Beeswax; Propolis; Royal jelly; Honey
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/01Hydrolysed proteins; Derivatives thereof
    • A61K38/012Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018Hydrolysed proteins; Derivatives thereof from animals from milk
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Insects & Arthropods (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Animal Husbandry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

ABSTRACT The composition for wound healing facilitates healing of damaged tissues, promotes tissue and cell growth, protects cells and tissues, and reduces scar tissue. The composition includes hydrolyzed collagen, whey, and magnesium stearate. The composition for wound healing demonstrates improved flow, increasing the ease of manufacturing and application to a wound site. The hydrolyzed collagen may include bovine sourced hydrolyzed collagen and marine sourced hydrolyzed collagen. The composition may also include an additive, such as a therapeutic agent, an antimicrobial, a vitamin, or a preservative. CA 3069167 2020-01-22

Description

Attorney Ref.: 1466P001CA01 COMPOSITION FOR WOUND HEALING
FIELD OF INVENTION
The composition for wound healing relates to wound healing, and particularly to a method and composition for wound healing in animals or humans that provides for administering a composition comprising hydrolyzed collagen and magnesium stearate.
BACKGROUND
Just as nature has provided the skin as a barrier for protection it has also provided mechanisms for skin repair. Depending upon the nature of the injury, this repair process may take hours, days, months, or even years. Many factors determine the length of time it takes for injured skin to heal. Pathogenic contaminants may enter the body through the wound until the skin's integrity is restored. For this reason, it is desirable to heal open wounds as quickly as possible.
Open wounds in the skin are a potential gateway for infectious or contaminating material to enter the body. The skin is a protective barrier to external contaminants. When the skin is damaged with an open breach, these contaminants are free to enter the body. Once inside the body, these contaminants may have effects of varying degrees, but almost always become more difficult to treat, and consequently slow the process of healing the original wound.
In order to fight infection, wound management traditionally involves an initial cleansing of the affected area to remove any contaminants, such as dirt, clothing particles, or other debris. Damaged tissue and foreign materials are removed when necessary, and Attorney Ref.: 1466P001CA01 antiseptic agents are applied to sterilize the injured area. Sterile dressings are often applied, and are periodically changed to keep the injured area as clean and sterile as possible.
Complex biological mechanisms occur during the healing process, such as chemical signals attracting fibroblast cells to the wound site, which ultimately generate connective structures, mainly of collagen. Endothelial cells generate new blood capillaries that nurture the new growth. Cell growth continues until the open wound is filled by forming permanent new tissue.
Recently, compositions containing collagen and hydrolyzed collagen have demonstrated improved wound healing capabilities. However, the manufacture and application of these products can be challenging. Particularly where specific mixtures of different collagen components are desired, the viscosity of the composition during manufacture may lead to mix variations and flow problems through critical equipment, causing delays, loss of product, and increased cost of production.
Thus, a composition for wound healing solving these problems is desired.
SUMMARY OF THE INVENTION
A method and composition for wound healing facilitates healing of damaged tissues, promoting tissue and cell growth, protecting cells and tissues, and reducing scar tissue. The composition includes proteinaceous amino acids, including hydrolyzed collagen, whey, and magnesium stearate. In some applications, the composition may include additives, such as therapeutic agents, antimicrobials, vitamins, or preservatives. In an embodiment, the hydrolyzed collagen may include one or more of bovine derived hydrolyzed collagen and marine derived hydrolyzed collagen.
2 Attorney Ref.: 1466P001CA01 In one aspect, the present disclosure describes a composition for wound healing, comprising: about 30% to about 90% by weight hydrolyzed collagen; about 0.5%
to about 60%
by weight whey; and magnesium stearate.
In a second aspect, the present disclosure describes a method of treating a wound, comprising: administering to a patient a wound healing composition, the wound healing composition comprising a hydrolyzed collagen, a whey protein, and magnesium stearate.
In a third aspect, this document discloses a topical composition for wound healing, comprising: about 30% to about 90% by weight hydrolyzed collagen; about 0.5%
to about 60%
by weight whey; and magnesium stearate.
In a fourth aspect, this document discloses the use of a topical wound healing composition for treating a wound, wherein the topical wound healing composition comprises a hydrolyzed collagen, a whey protein, and magnesium stearate.
In a fifth aspect, this document discloses use of a topical wound healing composition to treat a wound, the topical wound healing composition comprising a hydrolyzed collagen, a whey protein, and magnesium stearate.
These and other features of the composition for wound healing will become readily apparent upon further review of the following specification.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The method and composition for wound healing facilitates healing of damaged tissues, promoting tissue and cell growth, protecting cells and tissues, and reducing scar tissue.
The composition includes proteinaceous amino acids, including hydrolyzed collagen, whey, and magnesium stearate. The proteinaceous amino acids may facilitate tissue and cell growth as well as wound healing. The magnesium stearate acts as a lubricant, improving the flow of the
3 Date Recue/Date Received 2023-02-13 Attorney Ref.: 1 46 6P00 1 CAO 1 composition. This improved flow renders the composition both easier to manufacture (easier to manipulate into storage vessels such as tubes for resale) and easier to apply to a sensitive wound site.
In some applications, the composition may include additives, such as therapeutic agents, antimicrobials, vitamins, or preservatives. In an embodiment, the hydrolyzed collagen may include one or more of bovine derived hydrolyzed collagen and marine derived hydrolyzed collagen.
3a Date Recue/Date Received 2023-02-13 Attorney Ref.: 1466P001CA01 As used herein to define Daltons, the term "about" shall mean within 5,000 Daltons. As used herein to define a weight by volume percentage, the term "about" shall mean within 1% of the specified concentration.
Hydrolyzed collagen is a collagen hydrolysate polypeptide having a molecular weight lower than native collagen. Hydrolyzed collagen may be obtained by hydrolysis of native collagen. This may be accomplished by one of four methods: (1) alkaline hydrolysis;
(2) enzymatic hydrolysis; (3) acid hydrolysis; and (4) synthetically, by fermentation. Any of these methods can be used to derive the hydrolyzed collagen from a collagen source.
The hydrolyzed collagen can be derived from any suitable collagen source. The collagen source can be, for example, a bovine (skin and tendon preferred), a porcine, a reptile, a marine, an avian, an equine, and/or a synthetic source. For example, the collagen can be derived from a combination of two or more collagen sources, e.g., a bovine source and a marine source. The marine source can include any fish. Preferably, the marine source includes salmon, tilapia, or a combination of salmon and tilapia.
The types of amino acid constituents and their sequences determine the beneficial healing qualities of hydrolyzed collagen. Hydroxylysine and hydroxyproline are amino acids found only in collagen and in no other medical protein hydrolysates.
Hydroxylysine is typically found in concentrations of from about 0.7 to about 1.2 wt. % in hydrolyzed collagen.
Bovine and porcine hydrolyzed collagens have high glycine, proline, hydroxyproline, and glutamic acid content. They also display hydrophilic properties. Bovine hydrolyzed collagen, for example, demonstrates strong hydrophilic properties and when used to treat wound sites, demonstrates increased perfusion and epithelialization and decreased inflammatory reaction. In contrast, marine derived, i.e., marine sourced, hydrolyzed collagen
4 Attorney Ref.: 1466P001CA01 has a different amino acid profile, with higher levels of aspartic acid, cysteine, glutamine, citruline, and asparagine.
Hydrolyzed whey protein offers another alternative amino acid profile, rich in glutamic acid, isoleucine, leucine, threonine, tyrosine, and valine.
Magnesium stearate functions primarily as a lubricant, and is understood to reduce inter-particle friction. The use of magnesium stearate improves the consistency of the final product and enhances flow through the manufacturing process.
Preferably, the composition includes hydrolyzed Type 1 collagen. While hydrolyzed collagen of any molecular weight may be used, the hydrolyzed collagen can be high molecular weight hydrolyzed collagen, hereinafter "HMW hydrolyzed collagen," having a molecular weight less than native collagen. For example, the HMW hydrolyzed collagen may have a molecular weight of from about 10,000 to about 300,000 Daltons, particularly from about 10,000 to about 95,000 Daltons. That is to say, the HMW collagen may have a molecular weight of about 10,000, 20,000, 30,000, 40,000, 50,000, 60,000, 70,000, 80,000, 90,000, 100,000, 110,000, 120,000, 130,000, 140,000, 150,000, 160,000, 170,000, 180,000, 190,000, 200,000, 210,000, 220,000, 230,000, 240,000, 250,000, 260,000, 270,000, 280,000, 290,000, or 300,000 Daltons.
In an embodiment, the composition can include mixtures of collagen from different collagen sources. For example, the composition can include bovine sourced collagen, marine sourced collagen, and whey protein. According to another embodiment, the proteinaceous amino acids in the composition can include bovine sourced hydrolyzed collagen, marine sourced hydrolyzed collagen, and hydrolyzed whey protein. The composition can further include elastin.
5 Attorney Ref.: 1466P001CA01 The composition may include about 30% by weight to about 90% by weight hydrolyzed collagen. For example, the composition may include about 30% by weight, about 35% by weight, about 40% by weight, about 45% by weight, about 50% by weight, about 55% by weight, about 60% by weight, about 65% by weight, about 70% by weight, about 75% by weight, about 80% by weight, about 85% by weight, or about 90% by weight hydrolyzed collagen.
One or more additional therapeutic agents may be included in the composition to further speed the healing process, decrease scarring and increase tissue strength. Examples of suitable therapeutic agents that may be combined with the hydrolyzed collagen are glycosaminoglycans (GAGs), particularly GAGs useful for cellular repair.
Antimicrobials may also be included in the composition to further enhance its bacteriostatic quality, as can antibiotics (such as tetracycline, streptomycin, and cephalosporin) and antibacterials (such as iodine, parachlorometaxylenol, ortho-phthalaldehyde, iodophors, quaternary ammonium compounds, and chlorhexidine gluconate or acetate). The composition may further include lipoic acid, one or more vitamins (e.g., vitamin A, vitamin B12, vitamin C, vitamin E), omega compounds or omega-3 fatty acid compounds ( e.g., ALA, EPA, DHA), antioxidants (e.g., superoxide dismutase, glutathione peroxidase, glutathione reductase), and/or phytochemicals (e.g., zeaxanthin, lutein). Also, it has been established that hydrolyzed collagen used as a carrier in powder form, paste or a lyophilized foam has hemostatic qualities when combined with thrombin to improve healing of wounds.
Glycosaminoglycans (GAGs) are polysaccharides found in vertebrate and invertebrate animals. Several GAGs have been found in tissues and fluids of vertebrate animals. The known GAGs are chondroitin sulfate, keratin sulfate, dermatic sulfate,
6 Attorney Ref.: 1466P001CA01 hyaluronic acid, heparin, and heparin sulfate. GAGs and collagen are the major structural elements of all animal tissue. Their synthesis is essential for proper repair, treatment, protection, and maintenance of all tissues.
A particularly preferred glycosaminoglycan is chondroitin sulfate, a polysulfated GAG. Chondroitin sulfate is a linear polymer occurring in several isomers, named for the location of the sulfate group. Chondroitin-4 sulfate is found in nasal and tracheal cartilages of bovines and porcines. It is also found in the bones, flesh, blood, skin, umbilical cord, and urine of these animals. Chondroitin-6 sulfate has been isolated from the skin, umbilical cord, and cardiac valves of the aforementioned animals. Chondroitin-6 sulfate has the same composition, but slightly different physical properties from the chondroitin-4 sulfate. These are the most common isomers used in the present composition. The polymers are also known as polysulfated glycosaminoglycans (PSGAGs), chondroitin polysulfate sodium, chondrin, sodium chondroitin polysulfate, and sodium chondroitin sulfate. For consistency, the term "chondroitin sulfate" will be recited for all chondroitin sulfate isomers throughout this specification. Chondroitin sulfate is involved in the binding of collagen, and is also directly involved in the retention of moisture in the tissue. These are both valuable chemical properties that aid the healing process.
Hydrolyzed collagen in combination with GAGs, specifically a PSGAG (such as chondroitin sulfate), can be useful for the prevention and treatment of wound diseases. The hydrolyzed collagen combines with a PSGAG to bond or adhere selectively to tissue, resulting in interference with and/or displacement of bacterial or other infectious agents. In addition, the combination product may exhibit anti-enzyme activity or the ability to inhibit enzyme activity.
7 Attorney Ref.: 1466P001CA01 Hyaluronic acid and other proteoglycans (PGs) can be included in the composition. The hydrolyzed collagen accelerates the healing process by allowing an injured tissue to repair itself by producing and remodeling more collagen and other proteoglycans (PGs). The building blocks for collagen production are the amino acids found in hydrolyzed collagen. Hyaluronic acid and other proteoglycans (PGs) provide the framework for collagen production to follow. The PGs hold water to provide an excellent environment for healing of the tissue to begin. When in the wound site, any unused collagen that was produced is simply degraded to the amino acid. The rate-limiting step in the production of collagen is the conversion of glucose to glucosamine for the production of hyaluronic acid and other glycosaminoglycans (GAGs).
The composition can include one or more therapeutic agents, such as an antibiotic, and/or one or more additives, such as glutamine, glycosaminoglycans, zinc, alginates, copper chlorophillan, fibronectin, silver, oxidized regenerated cellulose, cellulose, and/or honey.
The composition can include one or more cross-linking agents, such as, humectant, propylene glycol, sorbitol, and glycerine.
Further examples of this wound healing composition optimized for different applications include: about 30% to about 90% bovine sourced hydrolyzed collagen, about 20% to about 50% marine sourced hydrolyzed collagen; about 0.5% to about 60%
whey, and magnesium stearate. In a preferred embodiment, the marine sourced collagen may be sourced from salmon and the whey may be hydrolyzed whey. For example, the composition may include about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, or about 90% by weight bovine
8 Attorney Ref.: 1466P001CA01 sourced hydrolyzed collagen; about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% by weight marine sourced hydrolyzed collagen; and about 0.5%, about 2%, about 4%, about 6%, about 8%, about 10%, about 12%, about 14%, about 16%, about 18%, about 20%, about 22%, about 24%, about 26% about 28%, about 30%, about 32%, about 34%, about 36%, about 38%, about 40%, or about 60% by weight whey.
The composition may be used to heal topical and/or internal wound sites. For example, the composition may be used prior to and after surgery to minimize cell damage and to expedite wound healing. The composition may be useful during surgery to foster separation of tissue to prevent adhesion formation. The composition may be used as a filler .. for a wound site and remain in the wound site as it heals, becoming part of the granulated tissue.
The composition may be useful for applications relating to cosmetic and plastic surgery, e.g., as a filler for lines and wrinldes formed in the skin.
The composition may take a physical form used in topical administration, such as a gel, spray, powder, paste, foam, film for incorporation in a dressing bandage, or a topically applied patch. The composition may take a physical form used in internal administration, such as an injectable liquid or an orally ingestible liquid.
The powder form will preferably have a moisture content of about 2-10 wt. %
and a p1-1 range of 5.5 to 6.5. The powder composition will have an ash content of less than 2.5 wt. % and an isotonic point of 5.0 to 6.5. In use, the powder composition may be the preferred physical form for use with irregularly shaped wounds. Tunnel wounds, flaps, and other non-conformative sites may be managed with the powder composition because it easily conforms to any shape wound, and may be applied by a poofer bottle or otherwise blown into
9 Attorney Ref.: 1466P001CA01 difficult to reach wound sites. The powder is especially useful in wounds having a large amount of exudate, as the powder can absorb nearly 30 times its own weight. As the powder absorbs the exudate, a gel is formed, which completely fills the wound site, forming a mechanical barrier against bacterial infection. The powder does not exhibit the characteristic fly-away when being applied to the wound site, and administration is perfected due to the precise powder placement.
The gel form of the composition is especially useful in wounds with lesser amounts of exudate, in burns, and in surgical sites. Application of the gel can be dispensed through a tube, a syringe, or the reservoir in a topical patch. It is preferable to use about 60 wt. % collagen. The gel is formed by adding sterile water to collagen powder.
The gel has the added advantage of adding moisture to the wound site, as well as inherent bacteriostatic properties, and stays positioned where applied.
A film form of the medicament composition may be made by mixing the powdered form with deionized water under heat at 155-175 F. Cross-linking and other agents, such as humectant, propylene glycol, sorbitol, and glycerine, may be added to the mixture. A preservative (such as benzyl alcohol or paraben) can be added. The mixture is cast on a belt liner by knife on a roll coating machine to form a liquid film, which is oven-dried. The film form can also be formed by cooling the liquid solution. These films can be used for drug or other chemical delivery, especially in dental applications.
Antimicrobial and other medicinal agents can also be added to the film as needed for specific applications.
The composition may be formulated as a nutritional supplement. For example, at least one of vitamin A, vitamin C, vitamin E, vitamin B12, magnesium oxide, chelated manganese, grape seed extract, zinc, an alginate, cellulose, honey, chromium picolinate, Attorney Ref.: 1466P00ICA01 selenium, glutamine, black seed oil, alpha lipoic acid, mulberry leaf extract, berberine, and glycosaminoglycans can be added to the composition to produce a nutrient composition for oral intake.
The composition can be sterilized by techniques known in the art, e.g., .. autoclaving, electron beam sterilization, ethylene oxide (E0) sterilization, and gamma sterilization. In addition to providing a sterile final product, sterilization can increase cross-linking, solubility, and/or humidity.
It is to be understood that the present composition is not limited to the embodiments described above, but encompasses any and all embodiments within the scope of the following claims.

Claims (22)

Attorney Ref.: 1466P001CA01What is claimed is:
1. A topical composition for wound healing, comprising:
about 30% to about 90% by weight hydrolyzed collagen;
about 0.5% to about 60% by weight whey; and magnesium stearate.
2. The topical composition for wound healing of claim 1, further comprising:
about 30% to about 90% by weight bovine sourced hydrolyzed collagen;
about 20% to about 50% by weight marine sourced hydrolyzed collagen;
about 0.5% to about 60% by weight whey; and magnesium stearate.
3. The topical composition for wound healing of claim 2, wherein the whey is hydrolyzed whey.
4. The topical composition for wound healing of claim 2, wherein the marine sourced hydrolyzed collagen is sourced from salmon.
5. The topical composition for wound healing of claim 2, wherein the composition comprises:
about 60% to about 70% by weight bovine sourced hydrolyzed collagen;
about 20% by weight marine sourced hydrolyzed collagen;

Date Recue/Date Received 2023-02-13 Attorney Ref.: 1466P001CA01 about 10% to about 20% by weight whey; and magnesium stearate;
wherein the marine sourced hydrolyzed collagen is sourced from salmon.
6. The topical composition for wound healing of claim 1, further comprising a therapeutic agent.
7. The topical composition for wound healing of claim 6, wherein the therapeutic agent is selected from the group consisting of: an antibiotic, glutamine, a glycosaminoglycan, zinc, an alginate, copper chlorophillan, fibronectin, silver, cellulose, and honey.
8. The topical composition for wound healing of claim 7, wherein the glycosaminoglycan is selected from the group consisting of: chondroitin sulfate, keratin sulfate, dermatic sulfate, hyaluronic acid, heparin, and heparin sulfate.
9. The topical composition for wound healing of claim 1, further comprising a cross-linking agent.
10. The topical composition for wound healing of claim 9, wherein the cross-linking agent is selected from the group consisting of: a humectant, propylene glycol, sorbitol, and glycerine.
11. The topical composition for wound healing of claim 1, further comprising an antimicrobial.

Date Recue/Date Received 2023-02-13 Attorney Ref.: 1466P001CA01
12. The topical composition for wound healing of claim 11, wherein the antimicrobial is selected from the group consisting of: tetracycline, streptomycin, cephalosporin, iodine, parachlorometaxylenol, and chlorhexidine.
13. The topical composition for wound healing of claim 1, further comprising a vitamin.
14. The topical composition for wound healing of claim 13, wherein the vitamin is selected from the group consisting of vitamin A, vitamin B12, vitamin C, and vitamin E.
15. The topical composition for wound healing of claim 1, further comprising an antioxidant.
16. The topical composition for wound healing of claim 15, wherein the antioxidant is selected from the group consisting of: superoxide dismutase, glutathione peroxidase, and glutathione reductase.
17. The topical composition for wound healing of claim 1 further comprising an ingredient selected from the group consisting of: black seed oil, alpha lipoic acid, mulberry leaf extract, berberine, lipoic acid, an omega fatty acid compound, zeaxanthin, lutein, and hyaluronic acid.
18. Use of a topical wound healing composition to treat a wound, the topical wound healing composition comprising a hydrolyzed collagen, a whey protein, and magnesium stearate.
19. The use of claim 18, wherein the topical wound healing composition comprises:

Date Recue/Date Received 2023-02-13 Attorney Ref.: 1466P001CA01 about 30% to about 90% by weight bovine sourced hydrolyzed collagen;
about 20% to about 50% by weight marine sourced hydrolyzed collagen;
about 0.5% to about 60% by weight whey; and magnesium stearate.
20. The use of claim 18, wherein the topical wound healing composition comprises:
about 60% to about 70% by weight bovine sourced hydrolyzed collagen;
about 20% by weight marine sourced hydrolyzed collagen;
about 10% to about 20% by weight whey; and magnesium stearate;
wherein the marine sourced hydrolyzed collagen is sourced from salmon.
21. The topical composition for wound healing of claim 7, whexein the cellulose comprises oxidized, regenerated cellulose.
22. The topical composition for wound healing of claim 17, wherein the omega fatty acid compound comprises an omega-3 fatty acid compound.
Date Recue/Date Received 2023-02-13
CA3069167A 2020-01-22 2020-01-22 Composition for wound healing Active CA3069167C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3069167A CA3069167C (en) 2020-01-22 2020-01-22 Composition for wound healing

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA3069167A CA3069167C (en) 2020-01-22 2020-01-22 Composition for wound healing

Publications (2)

Publication Number Publication Date
CA3069167A1 CA3069167A1 (en) 2021-07-22
CA3069167C true CA3069167C (en) 2024-03-19

Family

ID=76969166

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3069167A Active CA3069167C (en) 2020-01-22 2020-01-22 Composition for wound healing

Country Status (1)

Country Link
CA (1) CA3069167C (en)

Also Published As

Publication number Publication date
CA3069167A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
CA2409076C (en) Composition and method for growing, protecting, and healing tissues and cells
US7691829B2 (en) Composition and method for healing tissues
US10576037B2 (en) Compositions comprising placental collagen for use in wound healing
US20050208114A1 (en) Composition and method for healing tissues
US5696101A (en) Oxidized cellulose and vitamin E blend for topical hemostatic applications
CA2312558C (en) Collagen containing tissue adhesive
KR101918452B1 (en) Composition having Carboxymethyl Chitosan, cross-linked hyaluronic acid and collagen and, manufacturing methods for the same
US20020061842A1 (en) Method for sterilizing a native collagen in liquid medium, sterile native collagen obtained, compositions containing it and uses
PL202536B1 (en) Matrix protein compositions for wound healing
RU2188206C2 (en) Method of sterilization of native collagen in liquid medium, prepared sterile native collagen, composition comprising thereof and their using
US20200023042A1 (en) Composition for wound healing
KR102350526B1 (en) Method of preparing wound dressing composition for treating skin wounds having improved aggregation
US9782458B2 (en) Composition for tissue/cell repair
US20150216947A1 (en) Method and composition for tissue/cell repair
US9125892B2 (en) Composition for reduced scar formation of wounds
CA3069167C (en) Composition for wound healing
CN111012944A (en) Liquid dressing based on alginate and hyaluronic acid and preparation method thereof
US20230082131A1 (en) Compositions including amelogenin and uses thereof
US20240325503A1 (en) Wound healing and tissue repair composition and method using low molecular weight collagen and bioactive glass
US20230310553A1 (en) Wound healing and tissue repair composition and method using low molecular weight collagen and bioactive glass
KR102311547B1 (en) wound dressing material for hemostasis and wound treatment, and method for preparing same
US20240207351A1 (en) Tissue repair and wound healing composition and method using low molecular weight hydrolyzed collagen
WO2020053783A1 (en) A composition for use in the prevention and/or treatment of epistaxis
Subramanya et al. Current trends and controversies in periodontal dressing–A narrative review
US20240066180A1 (en) Therapeutic Compositions Containing a Bitterant for Veterinary Wound Care